title: Serum Visfatin, Adiponectin, and Tumor Necrosis Factor Alpha (TNF-α) Levels in Patients with Psoriasis and their Correlation with Disease Severity.
abstract: Psoriasis is a chronic, autoimmune, and inflammatory disease of unknown etiology, characterized by T lymphocyte mediated keratinocyte proliferation. In recent years the relationship between psoriasis and adipose tissue cytokines has been reported. Psoriasis as a triggering factor for the immune and metabolic disorders can be associated with diabetes mellitus, abnormal lipid metabolism, and metabolic syndrome. In this study we assessed the adipose tissue cytokines visfatin, adiponectin, and tumor necrosis factor-α (TNF-α) levels in psoriasis patients and evaluated the relationship between disease severity and cytokines. The study included 42 patients with psoriasis and 42 healthy individuals. Visfatin, adiponectin, and TNF-α levels were measured in both the psoriasis and the control group. The disease severity index was assessed in psoriatic patients by means of PASI. The relationship between visfatin, adiponectin, TNF-α, PASI score, and obesity was evaluated. When serum TNF-α, adiponectin, and visfatin levels of the patient group were compared with those of the control group, the TNF-α levels were statistically higher (p = 0.00) and the adiponectin levels were statistically lower (p = 0.024). The visfatin levels were higher in the psoriatic patients compared to the control group, but this difference was not statistically significant (p = 0.73). The relationship between PASI-TNF-α and between PASI-adiponectin was statistically significant (p = 0.009 and p = 0.004). A positive correlation was observed between body mass index (BMI) and visfatin (p = 0.031). These results indicate that TNF-α and adiponectin play a part in psoriasis etiopathogenesis and can be used as parameters to evaluate the severity of the disease. However, the role of visfatin in psoriasis pathogenesis is unclear. Further clinical studies are needed to clarify the effect of visfatin in psoriatic patients.
authors.affiliation: Betul Sereflican, MD, Abant Izzet Baysal University, Medical Faculty, Department of Dermatology, 12480 Golkoy-Bolu, Turkey; ozbetul@yahoo.com.
authors.forename: Betul
authors.initials: B
authors.lastname: Sereflican
authors.forename: Nadir
authors.initials: N
authors.lastname: Goksugur
authors.forename: Guler
authors.initials: G
authors.lastname: Bugdayci
authors.forename: Mualla
authors.initials: M
authors.lastname: Polat
authors.forename: Ali
authors.initials: A
authors.lastname: Haydar Parlak
mesh_terms: D052242:Adiponectin / Q000378:metabolism*; D000328:Adult; D016022:Case-Control Studies; D016207:Cytokines / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D054409:Nicotinamide Phosphoribosyltransferase / Q000378:metabolism*; D011565:Psoriasis / Q000378:metabolism* / Q000473:pathology*; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*; D055815:Young Adult
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha; D054409:Nicotinamide Phosphoribosyltransferase; C085455:nicotinamide phosphoribosyltransferase, human